A phase I trial of repeated @entity5 -infiltrating lymphocyte (TIL) infusion in XXXX .

@entity1 @entity32 @entity404 @entity39 @entity5 @entity221 @entity294 @entity2396 @entity1295 @entity310 @entity2146 @entity158 @entity551 @entity405 @entity320
The aim of the protocol was to evaluate the side-effects induced by repeated @entity5 -infiltrating lymphocyte (TIL) infusions in @entity1 with @entity320 ( @entity320 ). @entity1 were to receive four TIL infusions at given intervals: every 3 weeks (two @entity1 ), every 2 weeks (3 @entity1 ) and weekly (4 @entity1 ). All @entity1 were evaluated and received a total of 34 TIL infusions. The total number of TILs administered varied from 0.65 to 2.34 x 10(11) cells. TIL phenotypes were predominantly @entity405 + (two @entity1 ), @entity404 + (4 @entity1 ), @entity404 + then @entity405 + (two @entity1 ) or CD56+ (two @entity1 ). Autocytotoxicity was only observed for one culture. Six @entity1 presented at least one WHO grade 3 side-effect: @entity551 (5 @entity1 ), dyspnoea (two @entity1 ), @entity221 (one @entity1 ), @entity1295 (one @entity1 ), chills (two @entity1 ), @entity294 (one @entity1 ), @entity2146 (one @entity1 ), @entity158 (two @entity1 ). @entity551 was constantly seen in @entity1 who were given TILs every week. Two cases of minor @entity2396 were recorded. No objective response to treatment was observed; 1 stable disease occurred in one @entity1 and progression in eight. However, five @entity1 presented a partial response on a @entity5 site for 1-4 months. Three @entity1 presented signs of @entity32 or softening at one @entity5 site. Plasma @entity5 @entity39 factor alpha ( @entity310 ) levels were increased 1.2- to 22-fold after TIL infusion. TILs could be produced in sufficient quantity to perform this study, so repetitive infusions of TIL became possible on a weekly basis. However, no objective response was observed even when TIL infusions were performed weekly. An increase in circulating @entity310 was noted after TIL infusion.
